Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral Hypercalcemia of Malignancy.

How a duty to spend wisely on worker benefits could loosen PBMs’ grip on drug prices

Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the US drug market. Her job as a policy advocate at

December 18, 2024

Researchers explore patient’s perceptions of AI in radiology

AI-powered MRIs could cut the potentially toxic dyes used in traditional MRIs by up to 80 percent, but will patients embrace AI-driven brain scans?

December 11, 2024

New study links obesity to bacterium Megamonas

A recent study published in Cell Host & Microbe identifies a potential obesity-linked bacterium, Megamonas, from a large-scale cohort of obese individuals in China.

August 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.